[{"orgOrder":0,"company":"ClostraBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Butyrate","moa":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"ClostraBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"ClostraBio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ClostraBio \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Fatty Acids

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : An oral, targeted metabolite delivery platform enables butyrate to achieve its maximum therapeutic potential with an initial focus on helping patients who struggle with gastrointestinal issues like mild to moderate ulcerative colitis and food allergies.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 24, 2023

                          Lead Product(s) : Sodium Butyrate

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank